Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour.
Bertuzzi A, Castagna L, Quagliuolo V, Ginanni V, Compasso S, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Sarina B, Parra HS, Santoro A. Bertuzzi A, et al. Among authors: parra hs. Br J Cancer. 2003 Oct 6;89(7):1159-61. doi: 10.1038/sj.bjc.6601304. Br J Cancer. 2003. PMID: 14520438 Free PMC article.
Soft tissue and bone sarcomas.
Santoro A, Parra HS. Santoro A, et al. Among authors: parra hs. Cancer Chemother Biol Response Modif. 1999;18:489-97. Cancer Chemother Biol Response Modif. 1999. PMID: 10800499 Review. No abstract available.
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
Parra HS, Tixi L, Latteri F, Bretti S, Alloisio M, Gravina A, Lionetto R, Bruzzi P, Dani C, Rosso R, Cosso M, Balzarini L, Santoro A, Ardizzoni A. Parra HS, et al. Cancer. 2001 Aug 1;92(3):650-6. doi: 10.1002/1097-0142(20010801)92:3<650::aid-cncr1366>3.0.co;2-0. Cancer. 2001. PMID: 11505411 Clinical Trial.
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Di Bartolomeo M, et al. Among authors: parra hs. BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3. BMC Cancer. 2019. PMID: 30922323 Free PMC article. Clinical Trial.
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer.
Pressiani T, Balsano R, Giordano L, Milella M, Bergamo F, Bozzarelli S, Noventa S, Ferrrari D, Scartozzi M, Parra HS, Auriemma A, Soldà C, Zaniboni A, Zecchetto C, Rizzato MD, Rimassa L, Santoro A. Pressiani T, et al. Among authors: parra hs. Eur J Cancer. 2024 Aug;207:114196. doi: 10.1016/j.ejca.2024.114196. Epub 2024 Jun 29. Eur J Cancer. 2024. PMID: 38954899 Clinical Trial.
27 results